{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:34:35Z","timestamp":1787312075351,"version":"build-2736575974"},"reference-count":136,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mayo Clinic Hematological Malignancies Program","award":["U01CA271410"],"award-info":[{"award-number":["U01CA271410"]}]},{"name":"Paula and Roger Riney Foundation","award":["U01CA271410"],"award-info":[{"award-number":["U01CA271410"]}]},{"name":"Mayo Clinic and NCI","award":["U01CA271410"],"award-info":[{"award-number":["U01CA271410"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Several novel T-cell-based therapies have recently become available for multiple myeloma (MM). These T-cell redirecting therapies (TRTs) include chimeric antigen receptor T-cells (CAR-T) and bispecific antibodies (BiAbs). In both clinical trial and real-world data, these therapies have demonstrated high rates of deep clinical response, and some are now approved for second-line treatment for relapsed MM. The deep and sustained clinical responses these therapies are capable of inducing will require sophisticated response monitoring to provide meaningful information for patient care. Obtaining measurable residual disease (MRD) negativity has been validated as an independent positive prognostic marker for progression-free survival (PFS) and overall survival (OS) in both newly diagnosed and relapsed refractory patients with multiple myeloma. Assessment for MRD negativity was performed in all of the trials for FDA-approved TRT. Here, we summarize pertinent data for MRD assessment following TRT in MM and provide a rationale and structured framework for conducting MRD testing post TRT.<\/jats:p>","DOI":"10.3390\/cancers16193288","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T03:44:13Z","timestamp":1727408653000},"page":"3288","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3448-9452","authenticated-orcid":false,"given":"Kevin Guanwen","family":"Shim","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.hoc.2023.12.009","article-title":"Measurable Residual Disease and Decision-Making in Multiple Myeloma","volume":"38","author":"Derman","year":"2024","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/10408363.2023.2209652","article-title":"Advances in Minimal Residual Disease Monitoring in Multiple Myeloma","volume":"60","author":"Wijnands","year":"2023","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Medina-Herrera, A., Sarasquete, M.E., Jim\u00e9nez, C., Puig, N., and Garc\u00eda-Sanz, R. (2023). Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future. Cancers, 15.","DOI":"10.3390\/cancers15143687"},{"key":"ref_5","first-page":"1","article-title":"Best Practices for the Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma","volume":"18","author":"Bal","year":"2020","journal-title":"Clin. Adv. Hematol. Oncol. HO"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Romano, A., Palumbo, G.A., Parrinello, N.L., Conticello, C., Martello, M., and Terragna, C. (2019). Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00699"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of Minimal Residual Disease Standardised Assessment by FDG-PET\/CT in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Enrolled in the Imaging Sub-Study of the FORTE Trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101767","DOI":"10.1016\/j.tranon.2023.101767","article-title":"Evaluation of a Semi-Automated Approach for FDG PET Image Analysis for Routine Clinical Application in Patients with Multiple Myeloma","volume":"37","author":"Wellman","year":"2023","journal-title":"Transl. Oncol."},{"key":"ref_9","unstructured":"(2024, September 08). FDA News Release, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-first-next-generation-sequencing-based-test-detect-very-low-levels-remaining-cancer."},{"key":"ref_10","unstructured":"(2024, September 08). clonoSEQ Technical Information. Available online: https:\/\/www.clonoseq.com\/wp-content\/uploads\/2021\/08\/PNL-10027-03_clonoSEQ-Technical-Information.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow Standardization of Flow Cytometer Instrument Settings and Immunophenotyping Protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","article-title":"Consensus Guidelines and Recommendations for the Management and Response Assessment of Chimeric Antigen Receptor T-Cell Therapy in Clinical Practice for Relapsed and Refractory Multiple Myeloma: A Report from the International Myeloma Working Group Immunotherapy Committee","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_13","unstructured":"(2024, September 08). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma V.4.2024. \u00a9 National Comprehensive Cancer Network, Inc. 2024. All Rights Reserved. To View the Most Recent and Complete Version of the Guideline, Go Online to NCCN.org. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1445."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jtct.2022.03.019","article-title":"ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma","volume":"28","author":"Dhakal","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_15","unstructured":"(2024, September 08). Oncologic Drugs Advisory Commmittee (ODAC) Meeting 12 April 2024. Drug Topic: Use of Minimal Residual Disease (MRD) as an Endpoint in Multiple Myeloma Clinical Trials, Available online: https:\/\/www.fda.gov\/media\/177652\/download."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE Meta-Analysis: Evaluating Minimal Residual Disease as an Intermediate Clinical End Point for Multiple Myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/bloodadvances.2023010821","article-title":"Impact of Treatment Effect on MRD and PFS: An Aggregate Data Analysis from Randomized Clinical Trials in Multiple Myeloma","volume":"8","author":"Paiva","year":"2024","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease with Superior Survival Outcomes in Patients with Multiple Myeloma: A Meta-Analysis","volume":"3","author":"Munshi","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A Large Meta-Analysis Establishes the Role of MRD Negativity in Long-Term Survival Outcomes in Patients with Multiple Myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic Value of Minimal Residual Disease Negativity in Myeloma: Combined Analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal Residual Disease Status as a Surrogate Endpoint for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-Analysis","volume":"20","author":"Ludwig","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD Status in Relation to Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients: A Meta-Analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Turner, R., Kalff, A., Bergin, K., Gorniak, M., Fleming, S., and Spencer, A. (2022). The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.820605"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal Residual Disease Negativity Using Deep Sequencing Is a Major Prognostic Factor in Multiple Myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma and the Impact of Daratumumab in MAIA and ALCYONE","volume":"139","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.seminhematol.2023.02.001","article-title":"Measurable Residual Disease after CAR T-Cell Therapy","volume":"60","author":"Chokr","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma (MASTER): Final Report of the Multicentre, Single-Arm, Phase 2 Trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-142913","article-title":"Phase III Study of Daratumumab\/Rhuph20 (Nsc-810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (Mm) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study): SWOG S1803","volume":"136","author":"Krishnan","year":"2020","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2022-165441","article-title":"Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance as Part of the GEM2014MAIN Trial","volume":"140","author":"Puig","year":"2022","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"TPS8054","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8054","article-title":"Subcutaneous Daratumumab (DARA SC) plus Lenalidomide versus Lenalidomide Alone as Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Minimal Residual Disease (MRD) Positive after Frontline Autologous Stem Cell Transplant (ASCT): The Phase 3 AURIGA Study","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, Carfilzomib, and Dexamethasone in Patients with Relapsed Multiple Myeloma: Updated Results from IKEMA, a Randomized Phase 3 Study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of Daratumumab to Lenalidomide, Bortezomib, and Dexamethasone for Transplantation-Eligible Patients with Newly Diagnosed Multiple Myeloma (GRIFFIN): Final Analysis of an Open-Label, Randomised, Phase 2 Trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, Lenalidomide, and Dexamethasone or Lenalidomide Alone as Maintenance Therapy after Autologous Stem-Cell Transplantation in Patients with Multiple Myeloma (ATLAS): Interim Analysis of a Randomised, Open-Label, Phase 3 Trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.21.02228","article-title":"Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients with Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk","volume":"40","author":"Pawlyn","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of Sustained Minimal Residual Disease Negativity with Daratumumab-Combination Regimens in Relapsed and\/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR","volume":"39","author":"Casneuf","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","article-title":"Clinical Value of Measurable Residual Disease Testing for Assessing Depth, Duration, and Direction of Response in Multiple Myeloma","volume":"4","author":"Wong","year":"2020","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12672-024-00891-8","article-title":"Real-World Prognostic Significance of Attaining Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma","volume":"15","author":"Wang","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.hoc.2007.08.010","article-title":"Prognostic Factors and Staging in Multiple Myeloma","volume":"21","author":"Fonseca","year":"2007","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-Term Outcomes Following CAR T Cell Therapy: What We Know so Far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhang, H., Lan, H., Wu, J., and Xiao, Y. (2023). CAR-T Cell Therapy in Multiple Myeloma: Current Limitations and Potential Strategies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1101495"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current State and Next-Generation CAR-T Cells in Multiple Myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T Therapies in Multiple Myeloma: Unleashing the Future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Miller, K., Hashmi, H., and Rajeeve, S. (2024). Beyond BCMA: The next Wave of CAR T Cell Therapy in Multiple Myeloma. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1398902"},{"key":"ref_50","unstructured":"(2024, September 08). Carvykti, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/carvykti."},{"key":"ref_51","unstructured":"(2024, September 08). Abecama (Idecabtagene Vicleucel), Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-Cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and Safety of Cilta-Cel in Patients with Progressive MM after Exposure to Other BCMA-Targeting Agents","volume":"141","author":"Cohen","year":"2022","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-Cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.22.00690","article-title":"Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor\u2013T-Cell Therapy, in Chinese Patients with Relapsed\/Refractory Multiple Myeloma (CARTIFAN-1)","volume":"41","author":"Mi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-024-01530-z","article-title":"Long-Term Remission and Survival in Patients with Relapsed or Refractory Multiple Myeloma after Treatment with LCAR-B38M CAR T Cells: 5-Year Follow-up of the LEGEND-2 Trial","volume":"17","author":"Xu","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in Relapsed or Refractory Multiple Myeloma: The MagnetisMM-1 Phase 1 Trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 MagnetisMM-3 Trial Results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_62","unstructured":"(2024, September 08). Equecabtagene Autoleucel Injection Approved with Conditions by China NMPA, Available online: https:\/\/english.nmpa.gov.cn\/2023-06\/30\/c_940315.htm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/2643-3230.BCD-23-0044","article-title":"Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel","volume":"4","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed against B Cell Maturation Antigen, in Patients with Relapsed or Refractory Multiple Myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12185-023-03538-6","article-title":"Phase 2 Results of Idecabtagene Vicleucel (Ide-Cel, Bb2121) in Japanese Patients with Relapsed and Refractory Multiple Myeloma","volume":"117","author":"Minakata","year":"2023","journal-title":"Int. J. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s40291-023-00673-y","article-title":"Equecabtagene Autoleucel: First Approval","volume":"27","author":"Keam","year":"2023","journal-title":"Mol. Diagn. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1200\/JCO.2023.41.16_suppl.8025","article-title":"CT103A, a Novel Fully Human BCMA-Targeting CAR-T Cells, in Patients with Relapsed\/Refractory Multiple Myeloma: Updated Results of Phase 1b\/2 Study (FUMANBA-1)","volume":"41","author":"Li","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: Comparison of Idecabtagene Vicleucel with Real-World Outcomes in Relapsed and Refractory Multiple Myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3324\/haematol.2022.280482","article-title":"Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to Proteasome Inhibitors, Immunomodulatory Drugs and Anti-CD38 Antibody from the Prospective, Multinational LocoMMotion Study of Real-World Clinical Practice","volume":"108","author":"Mateos","year":"2022","journal-title":"Haematologica"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ferment, B., Lambert, J., Caillot, D., Lafon, I., Karlin, L., Lazareth, A., Touzeau, C., Leleu, X., Moya, N., and Harel, S. (2024). French Early Nationwide Idecabtagene Vicleucel Chimeric Antigen Receptor T-cell Therapy Experience in Patients with Relapsed\/Refractory Multiple Myeloma (FENIX): A Real-world IFM Study from the DESCAR-T Registry. Br. J. Haematol.","DOI":"10.1111\/bjh.19505"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of Extramedullary Multiple Myeloma on Outcomes with Idecabtagene Vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ajh.27023","article-title":"Natural History, Predictors of Development of Extramedullary Disease, and Treatment Outcomes for Patients with Extramedullary Multiple Myeloma","volume":"98","author":"Zanwar","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Que, Y., Xu, M., Xu, Y., Almeida, V.D.F., Zhu, L., Wang, Z., Wang, Y., Liu, X., Jiang, L., and Wang, D. (2021). Anti-BCMA CAR-T Cell Therapy in Relapsed\/Refractory Multiple Myeloma Patients with Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.755866"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T Cells for Myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-139802","article-title":"Results from Lummicar-2: A Phase 1b\/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1182\/blood-2023-184373","article-title":"Three-Year Follow-up on Efficacy and Safety Results from Phase 1 Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma","volume":"142","author":"Fu","year":"2023","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-136748","article-title":"Orvacabtagene Autoleucel (Orva-Cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized by a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence","volume":"136","author":"Colonna","year":"2020","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene Autoleucel (Orva-Cel), a B-Cell Maturation Antigen (BCMA)-Directed CAR T Cell Therapy for Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Update of the Phase 1\/2 EVOLVE Study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood-2022-160038","article-title":"Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633\/BMS-986354 in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.3324\/haematol.2022.282316","article-title":"Strategies to Optimize Chimeric Antigen Receptor T-Cell Therapy in Hematologic Malignancies: Chinese Experience","volume":"108","author":"Sun","year":"2023","journal-title":"Haematologica"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e120505","DOI":"10.1172\/jci.insight.120505","article-title":"Anti-CD19 CAR T Cells with High-Dose Melphalan and Autologous Stem Cell Transplantation for Refractory Multiple Myeloma","volume":"3","author":"Garfall","year":"2018","journal-title":"JCI Insight"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ajh.26486","article-title":"Anti-CD19 and Anti-BCMA CAR T Cell Therapy Followed by Lenalidomide Maintenance after Autologous Stem-cell Transplantation for High-risk Newly Diagnosed Multiple Myeloma","volume":"97","author":"Shi","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A Bispecific CAR-T Cell Therapy Targeting BCMA and CD38 in Relapsed or Refractory Multiple Myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1002\/cam4.5818","article-title":"A Second-generation CD38-CAR-T Cell for the Treatment of Multiple Myeloma","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41571-024-00913-y","article-title":"Just Scratching the Surface: Novel Treatment Approaches for Multiple Myeloma Targeting Cell Membrane Proteins","volume":"21","author":"Neri","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Omer, M.H., Shafqat, A., Ahmad, O., Alkattan, K., Yaqinuddin, A., and Damlaj, M. (2023). Bispecific Antibodies in Hematological Malignancies: A Scoping Review. Cancers, 15.","DOI":"10.3390\/cancers15184550"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-Term Follow-up from the Phase 1\/2 MajesTEC-1 Trial of Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Oriol","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S561","DOI":"10.1016\/S2152-2650(24)01689-6","article-title":"Long-Term Efficacy and Safety Results from the Phase 1\/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D\u00d7CD3 Bispecific Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"24","author":"Rasche","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for Treatment of Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","article-title":"LINKER-MM1 Study: Linvoseltamab (REGN5458) in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"41","author":"Lee","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"TPS8064","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064","article-title":"CAMMA 2: A Phase I\/II Trial Evaluating the Efficacy and Safety of Cevostamab in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) Who Have Triple-Class Refractory Disease and Have Received a Prior Anti-B-Cell Maturation Antigen (BCMA) Agent","volume":"41","author":"Kumar","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed\/Refractory Multiple Myeloma: Early Experience from a Phase I Study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/03007995.2023.2277850","article-title":"A Matching-Adjusted Indirect Comparison of the Efficacy of Elranatamab versus Physician\u2019s Choice of Treatment in Patients with Triple-Class Exposed\/Refractory Multiple Myeloma","volume":"40","author":"Mol","year":"2024","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s12325-023-02738-0","article-title":"Comparative Effectiveness of Teclistamab Versus Real-World Physician\u2019s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma","volume":"41","author":"Moreau","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clml.2023.02.006","article-title":"Comparative Efficacy of Teclistamab Versus Physician\u2019s Choice of Therapy in the Long-Term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma","volume":"23","author":"Mateos","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-World Analysis of Teclistamab in 123 RRMM Patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood-2023-174875","article-title":"Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study","volume":"142","author":"Mohan","year":"2023","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen \u00d7 CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"40","author":"Shah","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2020-134063","article-title":"A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE\u00ae (Bispecific T-Cell Engager) Molecule, in Relapsed\/Refractory (RR) Multiple Myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti\u2013B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"112043","DOI":"10.1016\/j.intimp.2024.112043","article-title":"Current Status of Bispecific Antibodies and CAR-T Therapies in Multiple Myeloma","volume":"134","author":"Szlasa","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Martino, M., Gamberi, B., Antonioli, E., Aquino, S., Pepa, R.D., Malerba, L., Mangiacavalli, S., Pezzatti, S., Bringhen, S., and Zamagni, E. (2024). Anti-BCMA CAR-T Cell-Based Therapies and Bispecific Antibodies in the Immunotherapy Era: Are We Ready for This?. Expert Rev. Hematol., ahead-of-print.","DOI":"10.1080\/17474086.2024.2357274"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2023.41.16_suppl.8002","article-title":"First Results from the RedirecTT-1 Study with Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"41","author":"Cohen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + Pomalidomide in Patients with Relapsed\/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"key":"ref_110","first-page":"260","article-title":"Preclinical Characterization of ISB 1342, a CD38 \u00d7 CD3 T-Cell Engager for Relapsed\/Refractory Multiple Myeloma","volume":"142","author":"Pouleau","year":"2023","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory Trial of a Biepitopic CAR T-Targeting B Cell Maturation Antigen in Relapsed\/Refractory Multiple Myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-023-00820-y","article-title":"Prognostic Value of Early Bone Marrow MRD Status in CAR-T Therapy for Myeloma","volume":"13","author":"Bansal","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.1182\/blood-2022-166465","article-title":"Updated Results of Fumanba-1: A Phase 1b\/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and Outcomes of Patients with Multiple Myeloma Receiving Salvage Therapy after BCMA-Directed CAR T Therapy","volume":"141","author":"Oekelen","year":"2023","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","article-title":"Population Pharmacokinetics and Exposure\u2013Response with Teclistamab in Patients with Relapsed\/Refractory Multiple Myeloma: Results from MajesTEC-1","volume":"18","author":"Miao","year":"2023","journal-title":"Target. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Dhakal, B., Sharma, S., Balcioglu, M., Shchegrova, S., Malhotra, M., Zimmermann, B., Billings, P.R., Harrington, A., Sethi, H., and Aleshin, A. (2022). Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.786451"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Zerdan, M.B., Kassab, J., Saba, L., Haroun, E., Zerdan, M.B., Allam, S., Nasr, L., Macaron, W., Mammadli, M., and Moussa, S.A. (2023). Liquid Biopsies and Minimal Residual Disease in Lymphoid Malignancies. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1173701"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Monick, S., and Rosenthal, A. (2024). Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas. Cancers, 16.","DOI":"10.3390\/cancers16101881"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/1078-0432.CCR-21-3430","article-title":"A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma","volume":"28","author":"Guerrero","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-023-00794-x","article-title":"Integrated Analysis of next Generation Sequencing Minimal Residual Disease (MRD) and PET Scan in Transplant Eligible Myeloma Patients","volume":"13","author":"Fonseca","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/bloodadvances.2021006762","article-title":"Mass Spectrometry vs Immunofixation for Treatment Monitoring in Multiple Myeloma","volume":"6","author":"Puig","year":"2022","journal-title":"Blood Adv."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-022-00624-6","article-title":"Mass-Fix Better Predicts for PFS and OS than Standard Methods among Multiple Myeloma Patients Participating on the STAMINA Trial (BMT CTN 0702 \/07LT)","volume":"12","author":"Dispenzieri","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"103378","DOI":"10.1016\/j.retram.2023.103378","article-title":"Serum Soluble BCMA Can Be Used to Monitor Relapse of Multiple Myeloma Patients after Chimeric Antigen Receptor T-Cell Immunotherapy","volume":"71","author":"Shen","year":"2023","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic Loss of BCMA as a Resistance Mechanism to CAR T Cell Therapy in a Patient with Multiple Myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ajh.27225","article-title":"Soluble B-cell Maturation Antigen in Multiple Myeloma","volume":"99","author":"Costa","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Wong, S.W., Shah, N., Ledergor, G., Martin, T., Wolf, J., Shui, A.M., Huang, C.-Y., and Martinez-Lopez, J. (2021). Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated with BCMA CAR-T Cells. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.783703"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD Profiling Defines Outcome and Unveils Different Modes of Treatment Resistance in Standard- and High-Risk Myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"key":"ref_130","first-page":"7","article-title":"Assessment of MRD in Patients with Hematologic Malignancies: Clinical Insights","volume":"18","author":"Fonseca","year":"2020","journal-title":"Clin. Adv. Hematol. Oncol. HO"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.clml.2023.11.001","article-title":"Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results from the Phase 2 MajesTEC-1 Study","volume":"24","author":"Martin","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1007\/s00277-023-05451-8","article-title":"Safe and Successful Teclistamab Treatment in Very Elderly Multiple Myeloma (MM) Patients: A Case Report and Experience from a Total of Three Octogenarians","volume":"102","author":"Dieterle","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jtct.2023.12.015","article-title":"Impact of Frailty on Outcomes After CAR T-Cell Therapy for Patients with Relapsed\/Refractory Multiple Myeloma","volume":"30","author":"Davis","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2021.02.011","article-title":"Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves","volume":"27","author":"Nawas","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-20-2188","article-title":"Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis","volume":"27","author":"Holthof","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-Cell Phenotypes Associated with Effective CAR T-Cell Therapy in Postinduction vs Relapsed Multiple Myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/19\/3288\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:04:30Z","timestamp":1760112270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/19\/3288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":136,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["cancers16193288"],"URL":"https:\/\/doi.org\/10.3390\/cancers16193288","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}